Literature DB >> 32633419

MHC class I transactivator NLRC5 in host immunity, cancer and beyond.

Steven X Cho1, Saptha Vijayan2, Ji-Seung Yoo1, Toshiyuki Watanabe1, Ryota Ouda1, Ning An1, Koichi S Kobayashi1,2.   

Abstract

The presentation of antigenic peptides by major histocompatibility complex (MHC) class I and class II molecules is crucial for activation of the adaptive immune system. The nucleotide-binding domain and leucine-rich repeat receptor family members CIITA and NLRC5 function as the major transcriptional activators of MHC class II and class I gene expression, respectively. Since the identification of NLRC5 as the master regulator of MHC class I and class-I-related genes, there have been major advances in understanding the function of NLRC5 in infectious diseases and cancer. Here, we discuss the biological significance and mechanism of NLRC5-dependent MHC class I expression.
© 2020 John Wiley & Sons Ltd.

Entities:  

Keywords:  cancer immune evasion; class I transactivator; major histocompatibility complex class I; regulatory factor X

Mesh:

Substances:

Year:  2020        PMID: 32633419      PMCID: PMC7884647          DOI: 10.1111/imm.13235

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  80 in total

1.  The nucleotide-binding domain of NLRC5 is critical for nuclear import and transactivation activity.

Authors:  Torsten B Meissner; Amy Li; Yuen-Joyce Liu; Etienne Gagnon; Koichi S Kobayashi
Journal:  Biochem Biophys Res Commun       Date:  2012-01-28       Impact factor: 3.575

Review 2.  NLRC5/CITA: A Key Player in Cancer Immune Surveillance.

Authors:  Sayuri Yoshihama; Saptha Vijayan; Tabasum Sidiq; Koichi S Kobayashi
Journal:  Trends Cancer       Date:  2017-01-10

3.  NLRC5 silencing ameliorates cardiac fibrosis by inhibiting the TGF‑β1/Smad3 signaling pathway.

Authors:  Hongtao Zhou; Xuefang Yu; Guiming Zhou
Journal:  Mol Med Rep       Date:  2017-07-14       Impact factor: 2.952

4.  Classical and nonclassical class I major histocompatibility complex molecules exhibit subtle conformational differences that affect binding to CD8alphaalpha.

Authors:  G F Gao; B E Willcox; J R Wyer; J M Boulter; C A O'Callaghan; K Maenaka; D I Stuart; E Y Jones; P A Van Der Merwe; J I Bell; B K Jakobsen
Journal:  J Biol Chem       Date:  2000-05-19       Impact factor: 5.157

5.  NLRC5 regulates cell proliferation, migration and invasion in hepatocellular carcinoma by targeting the Wnt/β-catenin signaling pathway.

Authors:  Yun-Yun Peng; Ying-Hua He; Chen Chen; Tao Xu; Lin Li; Ming-Ming Ni; Xiao-Ming Meng; Cheng Huang; Jun Li
Journal:  Cancer Lett       Date:  2016-03-11       Impact factor: 8.679

6.  NLRC5 mediates cytokine secretion in RAW264.7 macrophages and modulated by the JAK2/STAT3 pathway.

Authors:  Lin Li; Tao Xu; Cheng Huang; Yunyun Peng; Jun Li
Journal:  Inflammation       Date:  2014-06       Impact factor: 4.092

7.  The Obligate Intracellular Bacterium Orientia tsutsugamushi Targets NLRC5 To Modulate the Major Histocompatibility Complex Class I Pathway.

Authors:  Kyle G Rodino; Haley E Adcox; Rebecca K Martin; Vaidehi Patel; Daniel H Conrad; Jason A Carlyon
Journal:  Infect Immun       Date:  2019-02-21       Impact factor: 3.441

8.  A functionally defective allele of TAP1 results in loss of MHC class I antigen presentation in a human lung cancer.

Authors:  H L Chen; D Gabrilovich; R Tampé; K R Girgis; S Nadaf; D P Carbone
Journal:  Nat Genet       Date:  1996-06       Impact factor: 38.330

9.  NLRC5 regulates TGF-β1-induced proliferation and activation of hepatic stellate cells during hepatic fibrosis.

Authors:  Tao Xu; Ming-ming Ni; Xiao-feng Li; Xiao-ming Meng; Cheng Huang; Jun Li
Journal:  Int J Biochem Cell Biol       Date:  2015-11-26       Impact factor: 5.085

10.  A molecular model of the full-length human NOD-like receptor family CARD domain containing 5 (NLRC5) protein.

Authors:  János András Mótyán; Péter Bagossi; Szilvia Benkő; József Tőzsér
Journal:  BMC Bioinformatics       Date:  2013-09-17       Impact factor: 3.169

View more
  9 in total

1.  Enigmatic inflammasomes.

Authors:  Kathy Triantafilou
Journal:  Immunology       Date:  2021-03       Impact factor: 7.397

2.  Enigmatic inflammasomes - Sequel (Part 2).

Authors:  Kathy Triantafilou
Journal:  Immunology       Date:  2021-08       Impact factor: 7.215

Review 3.  Regulation of the antigen presentation machinery in cancer and its implication for immune surveillance.

Authors:  Adithya Balasubramanian; Thomas John; Marie-Liesse Asselin-Labat
Journal:  Biochem Soc Trans       Date:  2022-04-29       Impact factor: 4.919

Review 4.  Mechanisms of MHC-I Downregulation and Role in Immunotherapy Response.

Authors:  Brandie C Taylor; Justin M Balko
Journal:  Front Immunol       Date:  2022-02-28       Impact factor: 7.561

5.  Metabolomics of Acute vs. Chronic Spinach Intake in an Apc-Mutant Genetic Background: Linoleate and Butanoate Metabolites Targeting HDAC Activity and IFN-γ Signaling.

Authors:  Ying-Shiuan Chen; Jia Li; Sultan Neja; Sabeeta Kapoor; Jorge Enrique Tovar Perez; Chakrapani Tripathi; Rani Menon; Arul Jayaraman; Kyongbum Lee; Wan Mohaiza Dashwood; Shan Wang; Ke Zhang; Koichi Kobayashi; Praveen Rajendran; Roderick Dashwood
Journal:  Cells       Date:  2022-02-07       Impact factor: 6.600

Review 6.  The Role of Inflammasomes in Glomerulonephritis.

Authors:  Paula Anton-Pampols; Clara Diaz-Requena; Laura Martinez-Valenzuela; Francisco Gomez-Preciado; Xavier Fulladosa; Anna Vidal-Alabro; Joan Torras; Núria Lloberas; Juliana Draibe
Journal:  Int J Mol Sci       Date:  2022-04-11       Impact factor: 6.208

7.  CDK4/6 inhibitors sensitize gammaherpesvirus-infected tumor cells to T-cell killing by enhancing expression of immune surface molecules.

Authors:  Yiquan Wu; Prabha Shrestha; Natalie M Heape; Robert Yarchoan
Journal:  J Transl Med       Date:  2022-05-13       Impact factor: 5.531

8.  Screening of Specific and Common Pathways in Breast Cancer Cell Lines MCF-7 and MDA-MB-231 Treated with Chlorophyllides Composites.

Authors:  Keng-Shiang Huang; Yi-Ting Wang; Omkar Byadgi; Ting-Yu Huang; Mi-Hsueh Tai; Jei-Fu Shaw; Chih-Hui Yang
Journal:  Molecules       Date:  2022-06-20       Impact factor: 4.927

9.  Clinical and Molecular Correlates of NLRC5 Expression in Patients With Melanoma.

Authors:  Lei Lv; Qinqin Wei; Zhiwen Wang; Yujia Zhao; Ni Chen; Qiyi Yi
Journal:  Front Bioeng Biotechnol       Date:  2021-07-09
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.